Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. The Danish ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

There are also exciting CKD studies being done with newer classes of medications, such as the aldosterone synthase inhibitors, interleukin-6 antagonist (ziltivekimab) and endothelin receptor ...

Corvidia’s lead drug candidate – interleukin-6 inhibitor ziltivekimab (formerly COR-001) – is being developed as a therapy for reducing the risk of cardiovascular problems in CKD who have ...

Ziltivekimab is under clinical development by Novo Nordisk and currently in Phase III for Diastolic Heart Failure (HFpEF). According to GlobalData, Phase III drugs for Diastolic Heart Failure (HFpEF) ...

Atherosclerotic vascular disease remains the most common cause of ischemia, myocardial infarction, and stroke. Vascular function is determined by structural and functional properties of the arterial ...